Ernexa Therapeutics Inc. (NASDAQ:ERNA) Short Interest Up 68.8% in August

Ernexa Therapeutics Inc. (NASDAQ:ERNA) was the target of a significant increase in short interest in August. As of August 14th, there was short interest totaling 24,656 shares, an increase of 68.8% from the July 30th total of 14,605 shares. Currently, 1.5% of the company’s stock are short sold. Based on an average trading volume of 47,948 shares, the short-interest ratio is presently 0.5 days.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ERNA. Brookline Capital Markets initiated coverage on Ernexa Therapeutics in a research note on Thursday, May 7th. They issued a “buy” rating and a $30.00 price objective on the stock. Zacks Research raised Ernexa Therapeutics to a “hold” rating in a research note on Monday, May 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Friday, July 17th. Finally, Wall Street Zen lowered Ernexa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Ernexa Therapeutics presently has an average rating of “Hold” and a consensus target price of $30.00.

Institutional Trading of Ernexa Therapeutics

An institutional investor recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new stake in Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned about 0.39% of Ernexa Therapeutics as of its most recent filing with the Securities and Exchange Commission. 70.55% of the stock is owned by institutional investors and hedge funds.

Ernexa Therapeutics Price Performance

Shares of NASDAQ:ERNA remained flat at $4.57 during trading hours on Monday. 9,543 shares of the company’s stock were exchanged, compared to its average volume of 813,293. Ernexa Therapeutics has a 52 week low of $3.18 and a 52 week high of $71.50. The business’s 50-day moving average is $5.13 and its 200 day moving average is $6.51. The stock has a market cap of $7.46 million, a PE ratio of -0.32 and a beta of 2.57.

Ernexa Therapeutics (NASDAQ:ERNA) last released its quarterly earnings data on Thursday, August 6th. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.30) by ($0.10). Equities research analysts anticipate that Ernexa Therapeutics will post -18.02 earnings per share for the current fiscal year.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.